Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.
Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Nguyen PL, et al. Among authors: hoffman ke. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1081-5. doi: 10.1016/j.ijrobp.2009.09.015. Epub 2010 Mar 6. Int J Radiat Oncol Biol Phys. 2010. PMID: 20207497 Clinical Trial.
Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial.
Pinnix C, Perkins GH, Strom EA, Tereffe W, Woodward W, Oh JL, Arriaga L, Munsell MF, Kelly P, Hoffman KE, Smith BD, Buchholz TA, Yu TK. Pinnix C, et al. Among authors: hoffman ke. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1089-94. doi: 10.1016/j.ijrobp.2011.09.021. Epub 2011 Dec 14. Int J Radiat Oncol Biol Phys. 2012. PMID: 22172912 Free PMC article. Clinical Trial.
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer.
Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Bian SX, et al. Among authors: hoffman ke. Ann Oncol. 2012 Sep;23(9):2346-2352. doi: 10.1093/annonc/mds001. Epub 2012 Feb 21. Ann Oncol. 2012. PMID: 22357249 Free article.
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.
McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. McGuire SE, et al. Among authors: hoffman ke. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e39-46. doi: 10.1016/j.ijrobp.2012.08.036. Epub 2012 Oct 23. Int J Radiat Oncol Biol Phys. 2013. PMID: 23102837 Free PMC article.
242 results